EHMT2 and small cell lung carcinoma: Furthermore, pharmacological inhibition of WNT/β-catenin signaling reversed the NE phenotype of these derived T-SCLC cell lines [48], highlighting a key EHMT2-WNT/β-catenin axis during SCLC transformation.